Study

Cancer experts said on Sunday that the treatment of women with breast cancer the experimental “camesty” of “Astrazenica” reduces the risk of developing the disease or death in half, when the first sign of the disease withstands traditional types of treatment. The results of this study can change the way such types of cancer are treated. The results were presented to the American Clinical Oncology Association meeting in Chicago. The first time was used as a blood test known as “liquid biopsy” to determine the need to change the treatment in people with a general type of breast cancer, even before the growth of the crop appears in the rays. Dr. Elliona Telinski, an oncologist at the Valley Mount Count Center for Comprehensive Care to Cancer, said that “the changing treatment at an early stage of people with a positive breast cancer for hormone and negative receptors for the receptors of the human growth factor (-h2) led to a reduction in the risk of the disease or death.” “If the development of (the disease) occurs in the rays, we were already late,” said Telinski, who is also an expert in breast cancer, and explains that changing the treatment at an early stage before the disease changes the development of the disease can maintain their progress in his control. The FDA has not yet agreed to the drug “Kamesstrant”, but Telinski believes that the new data is likely to lead to a new model to treat the disease. The medical experiment and the experiment included 3 thousand and 256 patients in an advanced stage of breast cancer (-h2), which is the most common in which hormones stimulate, such as estrogen crop growth. Participants in the experiment received treatment for a period of at least 6 months with “aromatase” inhibitors, medicines that impede hormones that help with cancer growth. They also learned veiled medicines known as CDK 6/4 brakes such as “Novartis”, and Abrans of “Pfizer”, and Firzinho of Lily, which are medicines that impede one of the enzymes that stimulate the growth of cancerous crop. In patients with new blood tests, they showed that they had treatment, the researchers concluded that it took from the teaching of “chamber -straining” 16 months to develop the disease compared to only 9.2 months for those who remain on the current traditional treatment, which is a statistical. The study was published in the “New England Journal of Midsen” Medical on Sunday.